DK3675853T3 - Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom - Google Patents

Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom Download PDF

Info

Publication number
DK3675853T3
DK3675853T3 DK18766482.6T DK18766482T DK3675853T3 DK 3675853 T3 DK3675853 T3 DK 3675853T3 DK 18766482 T DK18766482 T DK 18766482T DK 3675853 T3 DK3675853 T3 DK 3675853T3
Authority
DK
Denmark
Prior art keywords
fabry
patients
disease
improving
methods
Prior art date
Application number
DK18766482.6T
Other languages
English (en)
Inventor
Jeff Castelli
Jay Barth
Nina Skuban
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3675853(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK3675853T3 publication Critical patent/DK3675853T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18766482.6T 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom DK3675853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
PCT/US2018/048257 WO2019046244A1 (en) 2017-08-28 2018-08-28 METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE

Publications (1)

Publication Number Publication Date
DK3675853T3 true DK3675853T3 (da) 2022-11-28

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18766482.6T DK3675853T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom
DK22194251.9T DK4176877T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK22194251.9T DK4176877T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom

Country Status (26)

Country Link
US (1) US20200222377A1 (da)
EP (3) EP4588476A1 (da)
JP (3) JP7755929B2 (da)
KR (2) KR102790184B1 (da)
CN (1) CN111770753A (da)
AR (1) AR112482A1 (da)
AU (2) AU2018326364B2 (da)
CA (1) CA3074450C (da)
CL (1) CL2020000491A1 (da)
DK (2) DK3675853T3 (da)
EA (1) EA202090564A1 (da)
ES (2) ES2931054T3 (da)
FI (1) FI4176877T3 (da)
HR (2) HRP20250064T1 (da)
HU (2) HUE060287T2 (da)
IL (3) IL272893B2 (da)
LT (2) LT4176877T (da)
MX (2) MX2020002229A (da)
PL (2) PL4176877T3 (da)
PT (2) PT4176877T (da)
RS (2) RS66515B1 (da)
SG (1) SG11202001707PA (da)
SI (1) SI4176877T1 (da)
SM (2) SMT202200459T1 (da)
TW (1) TWI845479B (da)
WO (1) WO2019046244A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CN111344912B (zh) 2017-08-28 2021-12-28 约翰·梅扎林瓜联合股份有限公司 同轴电缆连接器的天气防护壳体

Also Published As

Publication number Publication date
SMT202200459T1 (it) 2023-01-13
JP2025138638A (ja) 2025-09-25
MX2020002229A (es) 2020-07-20
TWI845479B (zh) 2024-06-21
RS63742B1 (sr) 2022-12-30
SG11202001707PA (en) 2020-03-30
PT3675853T (pt) 2022-11-28
HRP20250064T1 (hr) 2025-03-14
KR20250049561A (ko) 2025-04-11
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
EP3675853A1 (en) 2020-07-08
KR102790184B1 (ko) 2025-04-01
RS66515B1 (sr) 2025-03-31
IL272893B2 (en) 2024-07-01
IL310648A (en) 2024-04-01
SI4176877T1 (sl) 2025-03-31
AR112482A1 (es) 2019-10-30
EP3675853B1 (en) 2022-09-07
US20200222377A1 (en) 2020-07-16
AU2018326364B2 (en) 2024-08-29
IL272893A (en) 2020-04-30
CL2020000491A1 (es) 2020-09-11
IL272893B1 (en) 2024-03-01
DK4176877T3 (da) 2025-02-24
EP4176877B1 (en) 2024-12-04
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
LT3675853T (lt) 2022-12-12
EP4588476A1 (en) 2025-07-23
HUE060287T2 (hu) 2023-02-28
LT4176877T (lt) 2025-02-10
HRP20221366T1 (hr) 2023-01-06
TW201919619A (zh) 2019-06-01
ES2931054T3 (es) 2022-12-23
PL3675853T3 (pl) 2022-12-27
JP2020531550A (ja) 2020-11-05
AU2018326364A1 (en) 2020-04-09
BR112020003974A2 (pt) 2020-09-01
ES3013820T3 (en) 2025-04-15
PT4176877T (pt) 2025-02-24
PL4176877T3 (pl) 2025-04-07
AU2024266945A1 (en) 2024-12-19
FI4176877T3 (fi) 2025-03-06
CN111770753A (zh) 2020-10-13
WO2019046244A1 (en) 2019-03-07
JP2023051998A (ja) 2023-04-11
CA3074450C (en) 2024-10-01
JP7755929B2 (ja) 2025-10-17
CA3074450A1 (en) 2019-03-07
KR20200044908A (ko) 2020-04-29
HUE070433T2 (hu) 2025-06-28
EP4176877A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
DK3675853T3 (da) Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom
IL280566A (en) Systems and methods for affecting cardiac contractility and/or relaxation
EP3694529A4 (en) TRISPECIFIC PROTEINS AND METHOD OF USE
EP3600026A4 (en) IMPROVING THE QUALITY OF MEDICAL IMAGES USING MULTI-CONTRAST AND DEEP LEARNING
IL284414A (en) Methods and compositions for the treatment of fabry disease
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
IL258393A (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
DK3830119T3 (da) Anti-btn3a-antistoffer og deres anvendelse til behandling af kræft eller infektionssygdomme
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
EP3777967A4 (en) HEART IMPLEMENTATION DEVICE AND STIMULATION SYSTEM
EP3376977A4 (en) RECOVERY AND PROCESSING OF HUMAN EMBRYOS MADE IN VIVO
EP3681862C0 (en) BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCEMIA
DK3247352T3 (da) Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion
DK3749308T3 (da) Behandling af patienter med klassisk fabrys sygdom med migalastat
EP3290514C0 (en) APPLICATION OF PI4KIII.ALPHA PROTEIN AND ASSOCIATED MEMBRANE PROTEIN COMPLEX IN THE TREATMENT OF ALZHEIMER'S DISEASE
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
DK3882629T3 (da) Overvågning af mykotoksiner og deres metabolitter i blodet hos svin eller slagtekyllinger
DK3648471T3 (da) Høresystem med hjerterytmeovervågning og relateret fremgangsmåde
IL254970A0 (en) Recombinant lumpy skin disease virus knock-out mutant and uses thereof
DK3746469T3 (da) Antikoagulerende proteiner og deres anvendelse til behandling af sygdomme associeret med aktiveringen af neutrofiler
EP3814326A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
EP3703820A4 (en) USE OF MIR101 OR MIR128 IN THE TREATMENT OF EPILEPTIC DISORDERS
DK3721889T3 (da) Butyribacter intestini til anvendelse til forebyggelse og/eller behandling af inflammatorisk tarmsygdom
DK3937948T3 (da) Phytoecdysoner og derivater deraf til anvendelse i behandlingen af neuromuskulære sygdomme